Core Points - The company held a staff representative meeting on October 17, 2025, where Mr. Xia Sha was elected as a staff representative director for the seventh board of directors [1] - Mr. Xia Sha meets the qualifications and conditions for a director as per the Company Law and relevant regulations [1] - The composition of the seventh board of directors complies with legal requirements, ensuring that the number of directors who are also senior management or staff representatives does not exceed half of the total number of directors [1] Summary of Mr. Xia Sha's Profile - Mr. Xia Sha, born in May 1988, holds a bachelor's degree and has held various positions within the company, including deputy director and director of the electrical instrumentation workshop, and deputy and head of the engineering department [1] - Currently, Mr. Xia Sha serves as the head of the supply department [1] Compliance and Relationship - Mr. Xia Sha does not hold any shares in the company and has no relationships with shareholders holding more than 5% of the company's shares or with other directors and senior management [2] - He is not subject to any disqualifications as per the Company Law and relevant regulations, and has not faced penalties from regulatory bodies [2]

Core Viewpoint - Yong'an Pharmaceutical announced the election of Mr. Xia Sha as the employee representative director of the company's seventh board of directors during the employee representative assembly held on October 17, 2025 [1] Group 1 - The employee representative assembly was held on October 17, 2025 [1] - Mr. Xia Sha was elected as the employee representative director [1] - The seventh board of directors will consist of Mr. Xia Sha and six non-employee representative directors elected at the 2023 annual shareholders' meeting [1] - The term of the newly elected board members will last until the expiration of the seventh board's term [1]

特此公告。 潜江永安药业股份有限公司 董 事 会 二○二五年十月二十日 附件： 职工代表董事简历： 夏沙先生：1988年5月出生，本科学历。曾任公司电仪车间副主任、主任，公 司工程部副部长、部长。现任公司供应部部长。 证券代码：002365 证券简称：永安药业 公告编号：2025-60 潜江永安药业股份有限公司 关于选举第七届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为保证公司董事会的规范运作，根据《公司法》及《公司章程》的相关规定， 潜江永安药业股份有限公司（以下简称"公司"）于2025年10月17日召开了职工代 表大会，经民主讨论、表决，选举夏沙先生（简历见附件）为公司第七届董事会职 工代表董事，夏沙先生将与公司2023年年度股东大会选举产生的六名非职工代表董 事共同组成公司第七届董事会，任期自本次职工代表大会选举通过之日起至公司第 七届董事会任期届满之日止。 夏沙先生符合《公司法》《深圳证券交易所上市公司自律监管指引第1号—— 主板上市公司规范运作》及《公司章程》规定的有关董事任职资格和条件。本次选 举职工代表董事后，公司 ...

Core Points - Yong'an Pharmaceutical announced the acquisition of a 49.20% stake in its subsidiary Hubei Ling'an Technology Co., Ltd. for 27 million yuan, aiming to gain 100% ownership of the company [2] Group 1 - The board of directors approved the investment proposal during the ninth temporary meeting of the seventh board session, scheduled for September 24, 2025 [2] - The acquisition will not change the scope of the company's consolidated financial statements [2] - The company has already made the first payment to the sellers as per the share transfer agreement [2] Group 2 - Hubei Ling'an Technology has completed the necessary business registration changes and received a new business license from the market supervision administration [2]

Core Viewpoint - The company plans to acquire 49.20% equity of its subsidiary, Hubei Ling'an Technology Co., Ltd., for 27 million yuan, resulting in 100% ownership after the transaction is completed [1] Group 1 - The acquisition will be funded using the company's own funds [1] - Following the acquisition, the consolidation scope of financial statements will remain unchanged [1] - Hubei Ling'an Technology has completed the necessary business registration changes, with the legal representative changing from Zhang Yong to Chen Yong [1] Group 2 - The company has already paid the first installment of the acquisition price, with subsequent payments to follow [1] - The new business license clarifies the company's basic information and business scope [1] - Investors are reminded to pay attention to risks associated with the transaction [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-59 潜江永安药业股份有限公司 关于子公司湖北凌安科技有限公司完成 二、进展情况 根据《股权转让协议》的约定，公司已向交易对方支付完成第一期价款。近 日，凌安科技已办理完成上述事项相关的工商变更登记手续，并取得了由潜江市 市场监督管理局换发的《营业执照》，具体如下： | 变更事项 | 变更前内容 | 变更后内容 | | --- | --- | --- | | 负责人变更（法定 代表人、负责人、 | 张勇 | 陈勇 | | 首席代表、合伙事 | | | | 务执行人等变更） | | | | 市场主体类型(企 | 其他有限责任公司 | 有限责任公司(自然人投 | | 业类型)变更 | | 资或控股的法人独资) | （1）变更信息如下： | | 股东名称：夏昌培，认缴出资额：113.36 | | | --- | --- | --- | | | 万，币种：人民币，认缴出资方式：货 | | | | 币，认缴出资时间：2018-11-06；股东 | | | | 名称：张勇，认缴出资额：662.62 万， | 股东名称：潜江永安药业 | | 投资人变更（包括 ...

Meeting Overview - The second extraordinary general meeting of shareholders for 2025 was held on October 15, 2025, at 14:30, combining on-site and online voting methods [1][2] - A total of 525 shareholders attended the meeting, representing 77,902,515 shares, which is 26.9424% of the total voting shares [3][4] Voting Results - The proposal to change the business scope, increase the number of board members, and amend the Articles of Association was approved with 99.7578% of the votes in favor, totaling 77,713,815 shares [6][8] - The proposal to amend the governance system was also approved, with 99.7528% of the votes in favor for the amendment of the Shareholders' Meeting Rules [9][11] - The proposal to revise the Board Meeting Rules received 99.7434% approval [12][14] - The proposal to amend the Independent Director Work System was approved with 99.7558% of the votes in favor [15][17] Legal Compliance - The meeting's procedures, including the convening, attendance, and voting, were confirmed to comply with relevant laws and regulations by the witnessing lawyers from Shanghai Jintiancheng (Wuhan) Law Firm [17]

Core Viewpoint - Huanggang Yong'an Pharmaceutical Co., Ltd., a significant shareholder of Qianjiang Yong'an Pharmaceutical Co., Ltd., plans to reduce its shareholding without affecting the company's control [1][2]. Group 1: Shareholding Reduction Announcement - On July 25, 2025, the company disclosed a pre-announcement regarding the planned share reduction by its controlling shareholder, Huanggang Yong'an, who holds 10,529,232 shares (3.5731% of total shares) [1]. - Huanggang Yong'an intends to reduce its holdings by up to 2,632,300 shares (0.8933% of total shares) within three months following the pre-announcement [1]. Group 2: Implementation of Share Reduction - On September 9, 2025, the company reported that Huanggang Yong'an had completed its share reduction plan, having sold 410,000 shares (0.1391% of total shares) on September 4, 2025 [2][3]. - The reduction was executed at a price range of 17.02 to 19.02 yuan per share [2]. Group 3: Compliance and Impact - The share reduction was conducted in compliance with relevant laws and regulations, ensuring no breach of prior commitments [3]. - The reduction will not lead to a change in the company's control or affect its governance structure and ongoing operations [3].

上海市锦天城（武汉）律师事务所 关于潜江永安药业股份有限公司 二○二五年第二次临时股东会的 法律意见书 地址：武汉市江汉区云霞路 187 号民生金融中心 8 层 03-05 电话：027-83828888 邮编：430030 上海市锦天城（武汉）律师事务所 法律意见书 上海市锦天城（武汉）律师事务所 关于潜江永安药业股份有限公司 二○二五年第二次临时股东会的 法律意见书 致：潜江永安药业股份有限公司 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受潜江永安药业 股份有限公司（以下简称"公司"）的委托，委派本律师出席公司二○二五年第 二次临时股东会（下简称"本次股东会"），就公司召开本次股东会的有关事宜， 根据《中华人民共和国公司法》（以下简称《公司法》）《上市公司股东会规则》 等法律、法规、规章和其他规范性文件以及《潜江永安药业股份有限公司章程》 （以下简称《公司章程》）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉及的相 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-58 潜江永安药业股份有限公司 2025 年第二次临时股东会决议公告 网络投票时间：2025年10月15日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年10 月15日上午9:15—9:25,9:30-11:30 和下午13:00—15:00。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2025年10月15日（星期三）14:30 （2）通过深圳证券交易所互联网投票系统投票的时间为：2025年10月15日 9:15—15:00期间的任意时间。 2、现场会议召开地点：湖北省潜江经济开发区广泽大道2号潜江永安药业股 份有限公司（以下简称"公司"）二楼会议室 3、召开方式：本次股东会采取现场投票和网络投票相结合的方式。 4、股权登记日：2025年10月9日（星期四） 5、召集人：公司董事会； 6、主持人 ...